Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX® (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio

NEW BRUNSWICK, N.J., July 7, 2016 /PRNewswire/ -- Janssen Research & Development, LLC and Johnson & Johnson JNJ will provide a pre-recorded webcast focused on Phase 3 data recently presented for DARZALEX^® (daratumumab) as well as the company's immuno-oncology strategy and portfolio. The Webcast is intended for investors and other interested parties, and will be available as of Thursday, July 7, 2016.

The pre-recorded webcast features Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head of Oncology for Janssen R&D, recapping key data presentations on DARZALEX^® (daratumumab) from the CASTOR and POLLUX studies, which were featured at the 2016 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. Dr. Lebowitz will also describe the strategy and development plans for 15 compounds in the Janssen immuno-oncology portfolio.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." The webcast duration is approximately 16 minutes and will be available through the end of August.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/janssen-and-johnson--johnson-to-provide-webcast-presentation-on-phase-3-data-for-darzalex-daratumumab-and-the-janssen-immuno-oncology-strategy-and-portfolio-300294967.html

SOURCE Johnson & Johnson